Sassone-Corsi, M., Yam, J., Doherty, A., Guo, T., Zammit, N., Rashkovskii, M., Hoover, M., Tucker, D., Landyut, A., Zarin, P., Verma, S., Burgess, A., Moore, C., Uenishi, G., Hernandez, S., Gaddis, D., Agarwal, Y., Patel, C., Wickham, T., Chen, T. (2026). GNTI-932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg therapy for the treatment of Inflammatory Bowel Disease 2251383. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag141.113